{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:39:47Z","timestamp":1780922387716,"version":"3.54.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014476","name":"Pfizer BV","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014476","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"Novartis Pharma BV","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.semarthrit.2022.151974","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T17:31:02Z","timestamp":1643823062000},"page":"151974","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Baseline serum biomarkers of inflammation, bone turnover and adipokines predict spinal radiographic progression in ankylosing spondylitis patients on TNF inhibitor therapy"],"prefix":"10.1016","volume":"53","author":[{"given":"Judith","family":"Rademacher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Siderius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Gellert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freke R","family":"Wink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryna","family":"Verba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Maas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine M","family":"Tietz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Poddubnyy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke","family":"Spoorenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Arends","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.semarthrit.2022.151974_bib0001","doi-asserted-by":"crossref","first-page":"R104","DOI":"10.1186\/ar2496","article-title":"The relationship between inflammation and new bone formation in patients with ankylosing spondylitis","volume":"10","author":"Baraliakos","year":"2008","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.151974_bib0002","doi-asserted-by":"crossref","first-page":"e99685","DOI":"10.1371\/journal.pone.0099685","article-title":"Higher bone turnover is related to spinal radiographic damage and low bone mineral density in ankylosing spondylitis patients with active disease: a cross-sectional analysis","volume":"9","author":"Arends","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.semarthrit.2022.151974_bib0003","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kex475","article-title":"Functional relevance of radiographic spinal progression in axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort","author":"Poddubnyy","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.151974_bib0004","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1136\/ard.2008.091793","article-title":"Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine","volume":"68","author":"Landewe","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.151974_bib0005","doi-asserted-by":"crossref","unstructured":"van der Heijde D, Ramiro S. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. 2017;76(6):978\u201391.","DOI":"10.1136\/annrheumdis-2016-210770"},{"issue":"8","key":"10.1016\/j.semarthrit.2022.151974_bib0006","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1136\/annrheumdis-2015-207897","article-title":"Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS)","volume":"75","author":"Sieper","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.151974_bib0007","doi-asserted-by":"crossref","unstructured":"Karmacharya P, Duarte-Garcia A. Effect of therapy on radiographic progression in axial spondyloarthritis: a systematic review and meta-analysis. 2020.","DOI":"10.3410\/f.737245439.793576232"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.151974_bib0008","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/acr.23097","article-title":"Reduction in spinal radiographic progression in ankylosing spondylitis patients receiving prolonged treatment with tumor necrosis factor inhibitors","volume":"69","author":"Maas","year":"2017","journal-title":"Arthr Care Res"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.151974_bib0009","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/annrheumdis-2013-204055","article-title":"Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study","volume":"74","author":"Ramiro","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.151974_bib0010","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1002\/art.33465","article-title":"Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis","volume":"64","author":"Poddubnyy","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.151974_bib0011","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s13075-019-1970-3","article-title":"Alcohol consumption as a predictor of the progression of spinal structural damage in axial spondyloarthritis: data from the Catholic Axial Spondyloarthritis COhort (CASCO)","volume":"21","author":"Min","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.151974_bib0012","doi-asserted-by":"crossref","first-page":"R94","DOI":"10.1186\/ar3369","article-title":"Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study","volume":"13","author":"Arends","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"10.1016\/j.semarthrit.2022.151974_bib0013","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1093\/rheumatology\/kez025","article-title":"Added value of biomarkers compared with clinical parameters for the prediction of radiographic spinal progression in axial spondyloarthritis","volume":"58","author":"Rademacher","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.151974_bib0014","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1002\/art.22589","article-title":"Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis","volume":"56","author":"Maksymowych","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.151974_bib0015","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13075-020-02190-3","article-title":"Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis","volume":"22","author":"Jarlborg","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.1016\/j.semarthrit.2022.151974_bib0016","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1136\/annrheumdis-2013-203824","article-title":"Elevated serum level of the vascular endothelial growth factor predicts radiographic spinal progression in patients with axial spondyloarthritis","volume":"73","author":"Poddubnyy","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.semarthrit.2022.151974_bib0017","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1136\/annrheumdis-2014-205506","article-title":"Calprotectin serum level is an independent marker for radiographic spinal progression in axial spondyloarthritis","volume":"73","author":"Turina","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.151974_bib0018","doi-asserted-by":"crossref","first-page":"901","DOI":"10.3899\/jrheum.150897","article-title":"Serum vascular endothelial growth factor levels lack predictive value in patients with active ankylosing spondylitis treated with golimumab","volume":"43","author":"Braun","year":"2016","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.151974_bib0019","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3109\/03009742.2016.1152399","article-title":"Association between bone turnover markers, clinical variables, spinal syndesmophytes and bone mineral density in Mexican patients with ankylosing spondylitis","volume":"45","author":"Gamez-Nava","year":"2016","journal-title":"Scand J Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.151974_bib0020","doi-asserted-by":"crossref","first-page":"R125","DOI":"10.1186\/ar2537","article-title":"Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment","volume":"10","author":"Appel","year":"2008","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.151974_bib0021","doi-asserted-by":"crossref","first-page":"R98","DOI":"10.1186\/ar3823","article-title":"The effect of three years of TNF alpha blocking therapy on markers of bone turnover and their predictive value for treatment discontinuation in patients with ankylosing spondylitis: a prospective longitudinal observational cohort study","volume":"14","author":"Arends","year":"2012","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.151974_bib0022","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/annrheumdis-2011-200216","article-title":"High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis","volume":"71","author":"Heiland","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.151974_bib0023","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1002\/art.24888","article-title":"Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis","volume":"60","author":"Appel","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.151974_bib0024","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/art.38968","article-title":"Serum adipokine levels in patients with ankylosing spondylitis and their relationship to clinical parameters and radiographic spinal progression","volume":"67","author":"Syrbe","year":"2015","journal-title":"Arthrit Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.151974_bib0025","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13075-017-1350-9","article-title":"Serum levels of leptin and high molecular weight adiponectin are inversely associated with radiographic spinal progression in patients with ankylosing spondylitis: results from the ENRADAS trial","volume":"19","author":"Hartl","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.151974_bib0026","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0122693","article-title":"Spinal radiographic progression in patients with ankylosing spondylitis treated with TNF-\u03b1 blocking therapy: a prospective longitudinal observational cohort study","volume":"10","author":"Maas","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.151974_bib0027","first-page":"125","article-title":"Radiological scoring methods in ankylosing spondylitis. Reliability and change over 1 and 2 years","volume":"31","author":"Spoorenberg","year":"2004","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2022.151974_bib0028","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1002\/art.20446","article-title":"What is the most appropriate radiologic scoring method for ankylosingspondylitis? A comparison of the available methods based on the Outcome Measures in Rheumatology Clinical Trials filter","volume":"50","author":"Wanders","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.151974_bib0029","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/ard.2004.020503","article-title":"Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system","volume":"64","author":"Creemers","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.semarthrit.2022.151974_bib0030","first-page":"2048","article-title":"Selection of a method for scoring radiographs for ankylosing spondylitis clinical trials, by the Assessment in Ankylosing Spondylitis Working Group and OMERACT","volume":"32","author":"van der Heijde","year":"2005","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.151974_bib0031","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/art.38968","article-title":"Serum adipokine levels in patients with ankylosing spondylitis and their relationship to clinical parameters and radiographic spinal progression","volume":"67","author":"Syrbe","year":"2015","journal-title":"Arthrit Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.151974_bib0032","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1080\/03009742.2017.1299216","article-title":"Faecal calprotectin detects subclinical bowel inflammation and may predict treatment response in spondyloarthritis","volume":"47","author":"\u00d8stg\u00e5rd","year":"2018","journal-title":"Scand J Rheumatol"},{"issue":"9","key":"10.1016\/j.semarthrit.2022.151974_bib0033","doi-asserted-by":"crossref","first-page":"10104","DOI":"10.1096\/fj.201802691RR","article-title":"The alarmin S100A9 hampers osteoclast differentiation from human circulating precursors by reducing the expression of RANK","volume":"33","author":"Di Ceglie","year":"2019","journal-title":"FASEB J"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.151974_bib0034","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s10735-007-9117-2","article-title":"S100A8\/S100A9 and their association with cartilage and bone","volume":"38","author":"Zreiqat","year":"2007","journal-title":"J Mol Histol"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.151974_bib0035","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s00296-019-04301-z","article-title":"Serum visfatin levels in patients with axial spondyloarthritis and their relationship to disease activity and spinal radiographic damage: a cross-sectional study","volume":"39","author":"Hulejov\u00e1","year":"2019","journal-title":"Rheumatol Int"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.151974_bib0036","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00223-006-0155-7","article-title":"Insulin-like effects of visfatin on human osteoblasts","volume":"80","author":"Xie","year":"2007","journal-title":"Calcif Tissue Int"},{"issue":"1\u20132","key":"10.1016\/j.semarthrit.2022.151974_bib0037","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.mrfmmm.2009.06.012","article-title":"Pre-B cell colony enhancing factor\/NAMPT\/visfatin and its role in inflammation-related bone disease","volume":"690","author":"Moschen","year":"2010","journal-title":"Mutat Res"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.151974_bib0038","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/1756-185X.13829","article-title":"Effect of TNF-inhibitor therapy on spinal structural progression in ankylosing spondylitis patients: A systematic review and meta-analysis","volume":"23","author":"Ajrawat","year":"2020","journal-title":"Int J Rheumat Dis"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.151974_bib0039","first-page":"415","article-title":"Positive correlation between inflammation on sacroiliac joint MRI and serum C-terminal telopeptide of type-I collagen in ankylosing spondylitis but not in non-radiographic axial spondyloarthritis","volume":"35","author":"Kang","year":"2017","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.151974_bib0040","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00296-015-3397-8","article-title":"Cartilage collagen type II seromarker patterns in axial spondyloarthritis and psoriatic arthritis: associations with disease activity, smoking and HLA-B27","volume":"36","author":"Munk","year":"2016","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.151974_bib0041","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s13075-016-1200-1","article-title":"Serum biomarkers and changes in clinical\/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study","volume":"18","author":"Inman","year":"2016","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.151974_bib0042","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1186\/s13075-014-0413-4","article-title":"Calprotectin (S100A8\/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis","volume":"16","author":"Turina","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"10.1016\/j.semarthrit.2022.151974_bib0043","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1007\/s10067-017-3624-7","article-title":"Correlation of serum MMP3 and other biomarkers with clinical outcomes in patients with ankylosing spondylitis: a pilot study","volume":"36","author":"He","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.151974_bib0044","doi-asserted-by":"crossref","first-page":"R216","DOI":"10.1186\/ar4055","article-title":"Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy?","volume":"14","author":"Saad","year":"2012","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.151974_bib0045","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/ard.2007.084426","article-title":"Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis","volume":"68","author":"Visvanathan","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.semarthrit.2022.151974_bib0046","first-page":"1753","article-title":"Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept","volume":"34","author":"Woo","year":"2007","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.151974_bib0047","first-page":"880","article-title":"Leptin and adiponectin levels in patients with ankylosing spondylitis. The effect of infliximab treatment","volume":"28","author":"Derdemezis","year":"2010","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.151974_bib0048","first-page":"538","article-title":"Leptin and visfatin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-\u03b1 antagonist therapy","volume":"31","author":"Miranda-Filloy","year":"2013","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.151974_bib0049","first-page":"365","article-title":"Adiponectin and resistin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-alpha antagonist therapy","volume":"31","author":"Miranda-Filloy","year":"2013","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2022.151974_bib0050","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.3899\/jrheum.090346","article-title":"Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria","volume":"36","author":"Maksymowych","year":"2009","journal-title":"J Rheumatol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222000257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222000257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:07:59Z","timestamp":1758733679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017222000257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":50,"alternative-id":["S0049017222000257"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.151974","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Baseline serum biomarkers of inflammation, bone turnover and adipokines predict spinal radiographic progression in ankylosing spondylitis patients on TNF inhibitor therapy","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.151974","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"151974"}}